CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at the 39^th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 10:50 a.m. ET.

A live webcast of the presentation can be accessed on the investor page of Sage's website at investor.sagerx.com. A replay of the webcast will also be archived for up to 30 days on Sage's website following the conference.

More on Boston Chron

• State Street Elects Julio Portalatin and John Rhea to Its Board of Directors
• AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• Calvetta Phair, CEO of PEP Travel Group and Waldron McCritty, CEO of BE LUX, Alumni of ASCEND 2020, form teaming alliance to promote Luxury Hospitality
• Ameresco Announces Pricing of Public Offering of Class A Common Stock
• Bank on Boston partnership to support unbanked and underbanked Boston residents

About Sage Therapeutics

Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner. For more information, please visit www.sagerx.com.

---

Show All News | Report Violation